December 2015 Outline
OUR PERFORMANCE DECEMBER 2015 OUTLINE
Commercial Profitability Cash and Investments Shareholder Performance capital return management
Sales evolution Operating Free cash flow R&D investments Earnings per expenses conversion share Market share Capital development EBITDA evolution Receivables in investments Dividend emerging markets progression Operational footprint Working capital to sales ratio
2 KEY FACTS
Long term Short term 2001–2015 2010–2015
Commercial Sales: Sales: Performance +6% +3% CAGR CAGR
Profitability Expenses/ Expenses/ Sales 850bp Sales 200bp improvement improvement
Cash and capital Free Free cash flow 40% cash flow 36% management conversion: conversion:
Investments R&D spend R&D spend CAGR: +5% CAGR: +5%
Shareholder Dividend Dividend return* CAGR*: +28% CAGR**: +11%
* Dividends paid in 2015 for financial year 2014 3 LONG TERM 2001 – 2015
4 All figures as reported unless otherwise stated SALES EVOLUTION Commercial Performance
$bn 16 Group sales CAGR: +6% 14 Seeds sales CAGR: +9% 12 CP sales CAGR: +5% 10
8
6
4
2
0 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015
Crop Protection (including Professional Products) Seeds (including Flowers)
Source: Company estimates
5 Long Term 2001-2015 CROP PROTECTION Commercial MARKET SHARE Performance
Market share Market value % in $bn Technology transition to 23.0% SDHI 60 Financial fungicides crisis, credit constraint in 22.0% emerging 50 markets
21.0% 40
20.0% 30
19.0% 20
18.0% 10 Expansion in emerging markets
17.0% 0 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Crop Protection & Seed Care market Syngenta Crop Protection & Seed Care market share
Source: Phillips McDougall. Excludes professional products, includes intercompany sales
6 Long Term 2001-2015 SEEDS Commercial MARKET SHARE Performance
Market share Market value % in $bn
20.0% 60
Licensing 18.0% agreement with DuPont 50
16.0%
40 14.0%
12.0% 30
10.0% 20
8.0%
Trait offer expansion 10 6.0% Vegetables & Flowers acquisitions
4.0% 0 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Seeds market Syngenta Seeds market share
Source: Phillips McDougall Excludes: Flower seeds, public seeds and minor crops (e.g. forage, grasses, turf, alfalfa, sorghum)
7 Long Term 2001-2015 MARKET SHARE SUMMARY Commercial Performance
#1 in CP #3 in Seeds
2014 sales: 2014 sales: $11.4bn $3.2bn
Syngenta 20% Bayer 18% Monsanto 26% BASF 13% DuPont 20% Dow 10% Syngenta 8% Monsanto 9% Dow 4% DuPont 7% Bayer 3% Other 23% Other 39%
Source: Phillips McDougall. Crop Protection data excludes professional products, includes intercompany sales Seeds data excludes flower seeds, public seeds and minor crops (forage, grasses, turf, alfalfa, sorghum)
8 Long Term 2001-2015 BROAD CROP AND Commercial GEOGRAPHICAL FOOTPRINT Performance
2015 integrated sales by region Sales in 90+ countries 8 key crops
Total: Lawn & Garden Specialty crops US$12.8bn $0.6bn $1.9bn 52% Vegetables Rice North sales from $1.5bn $0.6bn America emerging markets EAME in 2015 Diverse 3.4bn Soybean field crops 3.9bn $2.5bn $1.1bn -4% CER +10% CER
Cereals LATAM APAC $1.7bn Sugar cane 3.6bn 1.8bn $0.3bn -5% CER -3% CER Corn $3.2bn
Source: Company results Source: Syngenta estimates
9 Long Term 2001-2015 OPERATING COST MANAGEMENT Profitability
% of Sales sales $bn 40 16
14
35
12 Expenses as reported 30 10
8
25
6
20 4 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015
Source: Company results
10 Long Term 2001-2015 EBITDA PERFORMANCE VS. CURRENCY IMPACT Profitability
Trait % of licensing Sales sales Trait agreement $bn licensing with 29 agreement KWS and 18 with Limagrain DuPont 16 27 EBITDA at CER 14 25 12
23 10
21 8
2012 6 19 trait EBITDA licensing, as reported seed 4 production 17 costs 2
15 0 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015
Sales Reported EBITDA % of Sales CER EBITDA % of Sales
Source: Company results
11 Long Term 2001-2015 FREE CASH FLOW CONVERSION Cash & capital management
Free cash flow before % of acquisitions $m EBITDA 1'800 Period 90% average 40% 1'600 Target 80% >40% 1'400 70%
1'200 60%
1'000 50%
800 40%
600 30%
400 20%
200 10%
- 0% 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015
Free Cash Flow before acquisitions EBITDA conversion
Source: Company results
12 Long Term 2001-2015 TRADE WORKING Cash & capital CAPITAL DEVELOPMENT management
% of sales 60% 52% 50% 47% 46% 43% 41% 42% 42% 40% 40% 39% 39% 40% 37% 37% 40% 35%
30%
20%
10%
0%
-10%
-20%
-30% 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015
Year end trade receivables % of sales Year end trade payables % of sales Year end inventory % of sales Average trade working capital % of sales
Source: Company results
13 Long Term 2001-2015 EXPANSION IN EMERGING MARKETS Cash & capital EVOLUTION OF WORKING CAPITAL management
Sales % of in $bn sales
9 40 Emerging market sales 8 % of total group 35 7 34% 52% 2005 2015 6 30
5 25 4
3 20
2 15 1
0 10 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015
Emerging market sales Total receivables % of sales
Source: Company results, Syngenta estimates
14 Long Term 2001-2015 EVOLUTION OF R&D INVESTMENTS Investments
Spend R&D % of sales $m Cumulated sales/R&D 2'500 12 R&D Post-merger Building the pipeline Globalization of R&D spend 11 2'000 +5% 10 CAGR
9 1'500
8
1'000 7 +7%
6 +7% 500 5 +2%
0 4 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015
Chemistry GM traits Breeding New technologies R&D % of sales Cumulated sales/R&D
Source: Company results, Syngenta estimates
15 Long Term 2001-2015 CAPITAL INVESTMENTS Investments
% of sales $m
7% -800
-700 6%
-600 5%
-500 4% -400 3% -300
2% -200
1% -100
0% 0 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015
Investments in fixed tangible and intangible assets less disposals Investments as % of sales
Source: Company results. Figures include intangible investments, net of disposals
16 Long Term 2001-2015 DIVIDEND PAYOUT Shareholder & CASH RETURN TO SHAREHOLDERS return
EPS* Dividend $ $ $m 25 Dividend payout 14 1'400 Cash return to shareholders Dividend CAGR** +28% 12 1'200 20 EPS CAGR +16% 10 1'000
15 8 800
6 600 10
4 400
5 2 200
0 0 0 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015
EPS Dividend Dividend payout Share repurchase * Fully diluted basis, excl. restructuring and impairment. CAGR as reported. ** 2001-2014 period Dividend paid in Swiss Francs. Numbers include dividend and par value reduction Source: Company results 17 Long Term 2001-2015 SHORT TERM 2010 – 2015
18 All figures as reported unless otherwise stated SALES EVOLUTION Commercial Performance
$bn
24 Group sales CAGR: +3% 22 20 Seeds sales CAGR: +2% 18 CP sales CAGR: +3% 16
14
12
10
8
6
4
2
0 2010 2011 2012 2013 2014 2015
Crop Protection (including Professional Products) Seeds (including Flowers)
Source: Company results
19 Short Term 2010-2015 SALES DEVELOPMENT Commercial Performance
CER sales CAGR: $m 6%
1'709 2'463
2'524 15'874
13'411 11'641
2010 Sales Volume Price 2015 Sales at 2010 Currency 2015 Sales rates
Source: Company results, Syngenta estimates
20 Short Term 2010-2015 CROP PROTECTION Commercial SALES GROWTH Performance
Q-o-Q growth rates
30.0%
25.0%
20.0%
15.0%
10.0%
5.0%
0.0%
-5.0%
-10.0%
-15.0% Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 2011 2012 2013 2014 2015
Syngenta* Top 6 companies** Source: Company results, Syngenta estimates * Including intercompany sales and professional products ** Top 6: BASF AgSolutions, Bayer Crop Science, Dow AgSciences, DuPont, Monsanto, Syngenta
21 Short Term 2010-2015 SEEDS Commercial SALES GROWTH Performance
Q-o-Q growth rates
40.0% Trait licensing agreement 30.0% with DuPont 20.0%
10.0%
0.0%
-10.0% 2012 trait -20.0% licensing deal
-30.0%
-40.0% Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 2011 2012 2013 2014 2015
Syngenta* Top 5 companies**
Source: Company results, Syngenta estimates * Excluding Flowers ** Top 5: Bayer CropScience, Dow AgSciences, DuPont (Pioneer), Monsanto, Syngenta
22 Short Term 2010-2015 EBITDA PERFORMANCE VS. CURRENCY IMPACT Profitability 2012 % trait Trait Sales of sales Trait licensing, licensing $bn licensing seed agreement agreement production with 16 with costs KWS and DuPont Limagrain 27
14
25 12
23 10
21 8
19 6
17 4 2010 2011 2012 2013 2014 2015
Sales Reported EBITDA % of Sales CER EBITDA % of Sales
Source: Company results
23 Short Term 2010-2015 OPERATING COST MANAGEMENT Profitability
% Sales of sales $bn
40 16
14
35 Expenses 12 as reported
10
30 8
6
25 4 2010 2011 2012 2013 2014 2015
Sales Function costs % of Sales
Source: Company results
24 Short Term 2010-2015 FREE CASH FLOW CONVERSION Cash & capital management
Free cash flow before % of acquisitions $m EBITDA 1'800 60% Period average 1'600 36% Target 50% 1'400 >40%
1'200 40%
1'000 30% 800
600 20%
400 10% 200
0 0% 2010 2011 2012 2013 2014 2015
Free Cash Flow before acquisitions EBITDA conversion
Source: Company results
25 Short Term 2010-2015 TRADE WORKING Cash & capital CAPITAL DEVELOPMENT management
In % of sales
60%
50% 46% 42% 39% 40% 37% 40% 35%
30%
20%
10%
0%
-10%
-20%
-30% 2010 2011 2012 2013 2014 2015
Year end trade receivables % sales Year end trade payables % sales Year end inventory % sales Average trade working capital % sales
Source: Company results
26 Short Term 2010-2015 EXPANSION IN EMERGING MARKETS Cash & capital WORKING CAPITAL DEVELOPMENT management
% Sales of sales $bn
55 9
8 50 7
45 6
5 40 4
35 3
2 30 1
25 0 2010 2011 2012 2013 2014 2015 Emerging market sales Emerging market sales % of total sales Total period end working capital % sales
Source: Company results, Syngenta estimates
27 Short Term 2010-2015 EVOLUTION OF R&D INVESTMENTS Investments
R&D R&D % of sales investment $m Cumulated sales/R&D
2'500 12.0 R&D spend 11.0 2'000 10.0 CAGR+5%
9.0 1'500 2010-2015 cumulated 8.0 growth =
1'000 $280m 7.0 Investment in new capabilities 6.0 500 Sustained investment in 5.0 chemistry Registration of full 0 4.0 GM trait portfolio 2010 2011 2012 2013 2014 2015 Global development Chemistry GM traits Breeding platform in Seeds New technologies R&D % of sales Cumulated sales/R&D
Source: Company results, Syngenta estimates
28 Short Term 2010-2015 CAPITAL INVESTMENTS Investments
% of sales $m
5.0% -800
4.5% -700
4.0% -600 3.5%
-500 3.0%
2.5% -400
2.0% -300
1.5% -200 1.0%
-100 0.5%
0.0% 0 2010 2011 2012 2013 2014 2015
Investments in fixed tangible and intangible assets less disposals Investments as % of sales
Source: Company results. Figures include intangible investments, net of disposals
29 Short Term 2010-2015 DIVIDEND PAYOUT Shareholder & CASH RETURN TO SHAREHOLDERS return
EPS* Dividend $ $ $m
35 Dividend payout 18 1'400 Cash return to shareholders Dividend CAGR** +11% 16 30 1'200
EPS CAGR +2% 14 25 1'000 12
20 10 800
8 15 600
6 10 400 4
5 200 2
0 0 0 2010 2011 2012 2013 2014 2015 2010 2011 2012 2013 2014 2015 EPS Dividend Dividend payout Share repurchase * Fully diluted basis, excl. restructuring and impairment. CAGR as reported. ** 2001-2014 period Dividend paid in Swiss Francs. Numbers include dividend and par value reduction Source: Company results
30 Short Term 2010-2015